Secondary analysis of the phase II SECOMBIT trial in BRAF-mutated metastatic melanoma (n=81): low vs high baseline serum thymidine kinase activity was linked to better 5-year OS (70.7% vs 36.9%) and total PFS (60.8% vs 35%); first PFS difference not significant.
Secondary analysisn = 81
Helgadottir et al. Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial